Amicus Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Amicus Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-09-30 | 2014-06-30 | 2014-02-04 | 2013-09-30 | 2013-02-04 | 2012-02-04 | 2011-09-30 | 2011-02-04 | 2010-02-04 | 2010-02-04 | 2009-02-04 | 2009-02-04 | 2008-02-04 | 2008-02-04 | 2007-12-31 | 2007-02-04 | 2007-02-04 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| net product sales | 154,688,000 | 125,249,000 | 149,706,000 | 141,517,000 | 126,669,000 | 110,403,000 | 115,082,000 | 103,501,000 | 94,503,000 | 86,270,000 | 88,096,000 | 81,691,000 | 80,731,000 | 78,715,000 | 82,154,000 | 79,545,000 | 77,413,000 | 66,402,000 | 70,571,000 | 67,437,000 | 62,353,000 | 60,525,000 | 55,293,000 | 48,768,000 | 44,130,000 | 34,046,000 | 32,644,000 | 20,596,000 | 21,309,000 | 16,696,000 | 10,874,000 | 7,158,000 | 4,169,000 | 2,127,000 | ||||||||||||||||||||||
| yoy | 22.12% | 13.45% | 30.09% | 36.73% | 34.04% | 27.97% | 30.63% | 26.70% | 17.06% | 9.60% | 7.23% | 2.70% | 4.29% | 18.54% | 16.41% | 17.95% | 24.15% | 9.71% | 27.63% | 38.28% | 41.29% | 77.77% | 69.38% | 136.78% | 107.10% | 103.92% | 200.20% | 187.73% | 411.13% | 684.96% | ||||||||||||||||||||||||||
| qoq | 23.50% | -16.34% | 5.79% | 11.72% | 14.73% | -4.07% | 11.19% | 9.52% | 9.54% | -2.07% | 7.84% | 1.19% | 2.56% | -4.19% | 3.28% | 2.75% | 16.58% | -5.91% | 4.65% | 8.15% | 3.02% | 9.46% | 13.38% | 10.51% | 29.62% | 4.29% | 58.50% | -3.35% | 27.63% | 53.54% | 51.91% | 71.70% | 96.00% | |||||||||||||||||||||||
| cost of goods sold | 15,217,000 | 11,698,000 | 14,836,000 | 13,279,000 | 11,261,000 | 13,567,000 | 11,324,000 | 9,946,000 | 9,114,000 | 6,942,000 | 9,384,000 | 13,436,000 | 8,197,000 | 7,582,000 | 7,851,000 | 11,696,000 | 8,380,000 | 6,539,000 | 9,417,000 | 8,399,000 | 6,676,000 | 6,552,000 | 6,945,000 | 5,596,000 | 5,367,000 | 4,055,000 | 4,344,000 | 4,310,000 | 3,135,000 | 2,615,000 | 1,790,000 | 1,061,000 | 775,000 | 344,000 | ||||||||||||||||||||||
| gross profit | 139,471,000 | 113,551,000 | 134,870,000 | 128,238,000 | 115,408,000 | 96,836,000 | 103,758,000 | 93,555,000 | 85,389,000 | 79,328,000 | 78,712,000 | 68,255,000 | 72,534,000 | 71,133,000 | 74,303,000 | 67,849,000 | 69,033,000 | 59,863,000 | 61,154,000 | 59,038,000 | 55,677,000 | 53,973,000 | 48,348,000 | 43,172,000 | 38,763,000 | 29,991,000 | 28,300,000 | 16,286,000 | 18,174,000 | 14,081,000 | 9,084,000 | 6,097,000 | 3,394,000 | 1,783,000 | ||||||||||||||||||||||
| yoy | 20.85% | 17.26% | 29.99% | 37.07% | 35.16% | 22.07% | 31.82% | 37.07% | 17.72% | 11.52% | 5.93% | 0.60% | 5.07% | 18.83% | 21.50% | 14.92% | 23.99% | 10.91% | 26.49% | 36.75% | 43.63% | 79.96% | 70.84% | 165.09% | 113.29% | 112.99% | 211.54% | 167.11% | 435.47% | 689.74% | ||||||||||||||||||||||||||
| qoq | 22.83% | -15.81% | 5.17% | 11.12% | 19.18% | -6.67% | 10.91% | 9.56% | 7.64% | 0.78% | 15.32% | -5.90% | 1.97% | -4.27% | 9.51% | -1.72% | 15.32% | -2.11% | 3.58% | 6.04% | 3.16% | 11.63% | 11.99% | 11.37% | 29.25% | 5.98% | 73.77% | -10.39% | 29.07% | 55.01% | 48.99% | 79.64% | 90.35% | |||||||||||||||||||||||
| gross margin % | 90.16% | 90.66% | 90.09% | 90.62% | 91.11% | 87.71% | 90.16% | 90.39% | 90.36% | 91.95% | 89.35% | 83.55% | 89.85% | 90.37% | 90.44% | 85.30% | 89.17% | 90.15% | 86.66% | 87.55% | 89.29% | 89.17% | 87.44% | 88.53% | 87.84% | 88.09% | 86.69% | 79.07% | 85.29% | 84.34% | 83.54% | 85.18% | 81.41% | 83.83% | ||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 60,848,000 | 27,839,000 | 30,190,000 | 26,160,000 | 24,683,000 | 28,329,000 | 35,029,000 | 40,704,000 | 35,149,000 | 41,499,000 | 63,871,000 | 52,970,000 | 78,319,000 | 81,517,000 | 85,596,000 | 59,333,000 | 63,003,000 | 64,117,000 | 79,293,000 | 70,419,000 | 69,611,000 | 89,120,000 | 91,912,000 | 58,892,000 | 70,981,000 | 64,593,000 | 57,217,000 | 138,227,000 | 34,660,000 | 40,798,000 | 40,641,000 | 31,985,000 | 30,876,000 | 32,457,000 | 18,281,000 | 23,425,000 | 20,971,000 | 17,234,000 | 16,113,000 | 12,049,000 | 9,978,000 | 367,829,000 | 10,110,000 | 327,882,000 | 279,624,000 | 28,113,000 | 237,507,000 | 20,052,000 | ||||||||
| selling, general, and administrative | 84,543,000 | 91,827,000 | 86,668,000 | 75,106,000 | 73,576,000 | 88,029,000 | 70,239,000 | 65,651,000 | 65,423,000 | 73,957,000 | 54,274,000 | 47,272,000 | 53,379,000 | 58,116,000 | 57,601,000 | 46,107,000 | 42,276,000 | 46,726,000 | 43,685,000 | 37,850,000 | 34,657,000 | 40,215,000 | 43,300,000 | 39,680,000 | 42,578,000 | |||||||||||||||||||||||||||||||
| restructuring charges | 3,143,000 | 6,045,000 | 11,000 | 8,000 | 50,000 | 7,000 | 26,000 | 10,000 | 15,000 | 3,502,000 | 1,522,000 | 1,522,000 | 1,522,000 | |||||||||||||||||||||||||||||||||||||||||||
| loss on impairment of assets | 1,702,000 | 1,134,000 | 6,616,000 | 465,427,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| depreciation and amortization | 1,852,000 | 1,837,000 | 2,041,000 | 2,170,000 | 2,182,000 | 2,154,000 | 2,182,000 | 2,228,000 | 2,206,000 | 1,257,000 | 1,311,000 | 1,286,000 | 1,334,000 | 1,411,000 | 1,518,000 | 1,520,000 | 1,567,000 | 1,604,000 | 2,547,000 | 2,496,000 | 2,039,000 | 1,764,000 | 1,514,000 | 1,116,000 | 1,154,000 | 991,000 | 375,000 | 396,000 | 13,899,000 | 429,000 | 12,207,000 | 10,483,000 | 721,000 | 9,342,000 | 620,250 | |||||||||||||||||||||
| total operating expenses | 148,945,000 | 121,503,000 | 118,899,000 | 106,579,000 | 100,441,000 | 124,557,000 | 107,450,000 | 110,578,000 | 104,249,000 | 116,964,000 | 121,040,000 | 102,095,000 | 133,147,000 | 146,472,000 | 146,449,000 | 110,248,000 | 107,867,000 | 112,918,000 | 125,989,000 | 111,799,000 | 107,022,000 | 132,030,000 | 137,371,000 | 100,477,000 | 115,193,000 | 111,270,000 | 97,783,000 | 172,467,000 | 65,105,000 | 70,263,000 | 284,316,000 | 53,158,000 | 55,409,000 | 46,723,000 | 48,542,000 | 43,001,000 | 38,045,000 | 26,943,000 | 24,058,000 | 17,109,000 | 14,741,000 | 543,865,000 | 15,174,000 | 480,495,000 | 410,421,000 | 37,592,000 | 354,310,000 | 201,611,000 | 201,611,000 | 139,517,000 | 139,517,000 | 105,667,000 | 105,667,000 | 29,230,750 | 80,208,000 | 80,208,000 |
| income from operations | -9,474,000 | -7,952,000 | 15,971,000 | 21,659,000 | 14,967,000 | -27,721,000 | -3,692,000 | -17,023,000 | -18,860,000 | -37,636,000 | -42,328,000 | -33,840,000 | -60,613,000 | -75,339,000 | -72,146,000 | -42,399,000 | -38,834,000 | -53,055,000 | -64,835,000 | -52,761,000 | -51,345,000 | -78,057,000 | -89,023,000 | -57,305,000 | -76,430,000 | -81,279,000 | -69,483,000 | -156,181,000 | -46,931,000 | -26,164,000 | -262,274,000 | -29,230,750 | ||||||||||||||||||||||||
| yoy | -163.30% | -71.31% | -532.58% | -227.23% | -179.36% | -26.34% | -91.28% | -49.70% | -68.88% | -50.04% | -41.33% | -20.19% | 56.08% | 42.00% | 11.28% | -19.64% | -24.37% | -32.03% | -27.17% | -7.93% | -32.82% | -3.96% | 28.12% | -63.31% | 62.86% | -86.03% | 40.01% | 47.16% | 47.16% | 60.22% | 60.22% | |||||||||||||||||||||||||
| qoq | 19.14% | -149.79% | -26.26% | 44.71% | -153.99% | 650.84% | -78.31% | -9.74% | -49.89% | -11.08% | 25.08% | -44.17% | -19.55% | 4.43% | 70.16% | 9.18% | -26.80% | -18.17% | 22.88% | 2.76% | -34.22% | -12.32% | 55.35% | -25.02% | -5.97% | 16.98% | -55.51% | 232.79% | -90.02% | 18.67% | 17.98% | 17.98% | 24.73% | 24.73% | 413.79% | 413.79% | -75.00% | |||||||||||||||||||
| operating margin % | -6.12% | -6.35% | 10.67% | 15.30% | 11.82% | -25.11% | -3.21% | -16.45% | -19.96% | -43.63% | -48.05% | -41.42% | -75.08% | -95.71% | -87.82% | -53.30% | -50.16% | -79.90% | -91.87% | -78.24% | -82.35% | -128.97% | -161.00% | -117.51% | -173.19% | -238.73% | -212.85% | -758.31% | -220.24% | |||||||||||||||||||||||||||
| other income: | 1,522,000 | 1,522,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest income | 843,000 | 812,000 | 1,416,000 | 1,081,000 | 1,370,000 | 1,540,000 | 1,671,000 | 1,471,000 | 1,737,000 | 2,199,000 | 1,972,000 | 563,000 | 356,000 | 133,000 | 186,000 | 108,000 | 50,000 | 165,000 | 328,000 | 518,000 | 865,000 | 1,515,000 | 2,259,000 | 2,752,000 | 2,599,000 | 2,639,000 | 3,090,000 | 2,721,000 | 2,913,000 | 1,737,000 | 1,190,000 | 753,000 | 759,000 | 460,000 | 331,000 | 307,000 | 316,000 | 158,000 | 171,000 | 55,000 | 36,000 | 14,605,000 | 36,000 | 14,454,000 | 14,100,000 | 55,000 | 14,018,000 | 1,538,500 | ||||||||
| interest expense | -11,565,000 | -11,455,000 | -11,958,000 | -12,692,000 | -12,512,000 | -12,436,000 | -12,827,000 | -12,986,000 | -12,492,000 | -11,844,000 | -11,095,000 | -9,620,000 | -8,257,000 | -8,147,000 | -8,164,000 | -8,165,000 | -8,150,000 | -7,992,000 | -8,277,000 | -6,784,000 | -3,635,000 | -3,729,000 | -3,767,000 | -4,026,000 | -4,625,000 | -6,454,000 | -8,639,000 | -4,715,000 | -4,560,000 | -59,000 | -2,274,000 | 7,997,000 | 7,997,000 | 4,792,000 | 4,792,000 | 3,447,000 | 3,447,000 | -337,750 | 2,481,000 | 2,481,000 | ||||||||||||||||
| other income | 1,015,000 | 550,000 | 2,505,000 | -3,263,000 | -3,717,000 | -4,966,000 | -2,879,000 | 3,833,000 | -10,902,000 | -5,938,000 | -18,628,000 | 13,634,000 | 7,268,000 | 1,902,000 | -172,000 | 237,000 | 234,000 | -3,200,000 | -810,000 | 3,019,000 | 5,326,000 | -8,316,000 | 646,000 | -3,481,000 | -877,000 | 1,086,000 | -2,039,000 | -1,039,000 | -5,316,000 | 2,764,000 | 2,044,000 | 2,400,000 | 610,000 | 252,000 | 231,000 | 231,000 | 302,124,000 | 302,124,000 | 208,688,000 | 208,688,000 | 158,936,000 | 158,936,000 | -295,500 | 116,923,000 | 116,923,000 | |||||||||||
| income before income tax | -19,181,000 | -18,045,000 | 7,934,000 | 6,785,000 | 108,000 | -43,583,000 | -31,660,000 | -24,705,000 | -40,517,000 | -53,219,000 | -70,079,000 | -29,263,000 | -61,246,000 | -81,451,000 | -80,296,000 | -50,476,000 | -46,700,000 | -64,082,000 | -73,594,000 | -63,284,000 | -48,789,000 | -88,587,000 | -89,885,000 | -62,060,000 | -83,834,000 | -120,131,000 | -77,071,000 | -159,214,000 | -61,494,000 | -221,016,000 | -221,016,000 | -187,331,000 | -187,331,000 | -150,185,000 | -150,185,000 | -116,923,000 | -116,923,000 | |||||||||||||||||||
| income tax expense | -5,239,000 | -3,641,000 | -15,805,000 | -2,715,000 | -911,000 | -3,809,000 | -4,525,000 | -1,582,000 | -3,703,000 | -361,000 | 47.16% | 47.16% | 540.87% | 540.87% | 28.45% | 28.45% | ||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -24,420,000 | -21,686,000 | 14,739,000 | -6,729,000 | -15,697,000 | -48,419,000 | -33,843,000 | -21,577,000 | -43,232,000 | -52,932,000 | -55,865,000 | -33,286,000 | -62,157,000 | -85,260,000 | -83,277,000 | -50,294,000 | -51,225,000 | -65,664,000 | -71,401,000 | -64,011,000 | -52,492,000 | -88,948,000 | -89,729,000 | -61,809,000 | -84,551,000 | -120,299,000 | -78,081,000 | -159,163,000 | -61,833,000 | -49,916,000 | -111,666,000 | -48,136,000 | -54,992,000 | -414,691,000 | -14,589,000 | -356,573,000 | -303,467,000 | -18,421,000 | -271,909,000 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 91,769,000 | 0.00% | 0.00% | ||||||||
| yoy | 55.57% | -55.21% | -143.55% | -68.81% | -63.69% | -8.53% | -39.42% | -35.18% | -30.45% | -37.92% | -32.92% | -33.82% | 21.34% | 29.84% | 16.63% | -21.43% | -2.41% | -26.18% | -20.43% | 3.56% | -37.92% | -26.06% | 14.92% | -61.17% | 36.74% | 141.00% | -30.08% | 230.65% | 12.44% | 2151.19% | -94.63% | 54.47% | 31.47% | -90.64% | 38.10% | 42.41% | 42.41% | 47.72% | 47.72% | |||||||||||||||||
| qoq | 12.61% | -247.13% | -319.04% | -57.13% | -67.58% | 43.07% | 56.85% | -50.09% | -18.33% | -5.25% | 67.83% | -46.45% | -27.10% | 2.38% | 65.58% | -1.82% | -21.99% | -8.03% | 11.54% | 21.94% | -40.99% | -0.87% | 45.17% | -26.90% | -29.72% | 54.07% | -50.94% | 157.41% | 23.87% | -55.30% | 131.98% | -12.47% | 2742.49% | -95.91% | 17.50% | 1547.40% | -93.23% | 17.80% | 17.24% | 17.24% | 21.47% | 21.47% | -276.62% | -276.62% | -168.85% | |||||||||||
| net income margin % | -15.79% | -17.31% | 9.85% | -4.75% | -12.39% | -43.86% | -29.41% | -20.85% | -45.75% | -61.36% | -63.41% | -40.75% | -76.99% | -108.31% | -101.37% | -63.23% | -66.17% | -98.89% | -101.18% | -94.92% | -84.19% | -146.96% | -162.28% | -126.74% | -191.60% | -353.34% | -239.19% | -772.79% | -290.17% | -298.97% | -1026.91% | -672.48% | -1319.07% | 0% | ||||||||||||||||||||||
| net income attributable to common stockholders per common share — basic and diluted | -80 | -70 | 50 | -20 | -50 | -160 | -110 | -70 | -150 | -180 | -190 | -120 | -210 | -300 | -290 | -190 | -190 | -250 | -270 | -250 | -200 | -350 | -350 | -240 | -360 | -560 | -410 | -840 | -330 | -280 | -690 | -340 | -390 | |||||||||||||||||||||||
| weighted-average common shares outstanding — basic and diluted | 308,254,256,000 | 307,689,207,000 | 304,380,502,000 | 304,690,596,000 | 303,773,922,000 | 302,903,009,000 | 295,164,515,000 | 295,759,435,000 | 292,797,002,000 | 291,336,750,000 | 289,057,198,000 | 289,223,709,000 | 291,970,562,000 | 288,481,741,000 | 271,421,986,000 | 267,464,637,000 | 266,398,516,000 | 264,369,317,000 | 258,867,380,000 | 259,161,799,000 | 257,973,329,000 | 256,968,248,000 | 240,421,001,000 | 254,674,422,000 | 238,089,824,000 | 213,519,287,000 | 185,790,021,000 | 189,162,841,000 | 188,621,423,000 | 175,977,700,000 | 160,796,841,000 | 143,000,718,000 | 142,770,629,000 | 140,656,109,000 | 129,122,175,000 | 118,724,882,000 | 99,994,125,000 | 95,743,416,000 | 78,889,346,000 | 67,212,764,000 | 49,621,188,000 | 13,235,755,000 | ||||||||||||||
| changes in fair value of contingent consideration payable | 1,995,000 | 337,000 | 251,000 | 1,584,000 | 567,000 | 115,000 | -1,188,000 | 1,734,000 | 3,288,000 | 1,021,000 | 471,000 | 464,000 | 1,034,000 | 715,000 | 931,000 | 645,000 | 789,000 | 480,000 | 1,383,000 | 600,000 | 1,300,000 | 300,000 | 1,100,000 | 1,050,000 | 4,578,000 | 10,186,000 | 3,152,000 | 1,300,000 | 100,000 | 1,000,000 | 505,000 | 13,878,000 | 13,878,000 | 13,286,000 | 13,286,000 | 10,974,000 | 10,974,000 | 6,154,000 | 6,154,000 | |||||||||||||||||
| income tax benefit | 6,805,000 | -13,514,000 | -4,836,000 | -2,183,000 | 3,128,000 | 287,000 | 14,214,000 | -4,023,000 | -1,481,250 | 182,000 | 2,193,000 | -727,000 | 156,000 | 251,000 | -717,000 | -168,000 | -1,010,000 | 51,000 | -339,000 | 1,392,000 | 164,683,000 | 253,000 | 453,000 | 12,220,000 | 8,708,000 | -2,127,000 | -2,127,000 | -1,677,000 | -1,677,000 | -1,559,000 | -1,559,000 | 173,750 | -1,351,000 | -1,351,000 | ||||||||||||||||||||||
| loss on extinguishment of debt | -257,000 | -7,276,000 | 952,000 | -1,116,000 | -1,116,000 | -1,180,000 | -1,180,000 | -1,180,000 | -1,180,000 | -1,182,000 | -1,182,000 | |||||||||||||||||||||||||||||||||||||||||||||
| loss on exchange of convertible notes | -4,501,000 | -36,123,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| change in fair value of derivatives | -7,600,000 | 4,861,000 | -230,830,000 | -230,830,000 | -196,887,000 | -196,887,000 | -162,085,000 | -162,085,000 | -133,287,000 | -133,287,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| selling, general and administrative | 44,303,000 | 38,765,000 | 31,867,000 | 29,172,000 | 27,396,000 | 21,647,000 | 19,311,000 | 19,132,000 | 17,469,000 | 42.41% | 42.41% | -314.55% | -314.55% | 21.61% | 21.61% | |||||||||||||||||||||||||||||||||||||||||
| depreciation | 1,201,000 | 1,073,000 | 973,000 | 969,000 | 851,000 | 812,000 | 823,000 | 896,000 | 767,000 | 673,000 | 395,000 | 353,000 | 508,000 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||||||||||||||||||||||||||||||||
| income before income tax benefit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax (expense)/benefit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax (expense)/ benefit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income | -37,800,000 | -27,133,000 | -24,288,000 | -17,149,000 | -14,614,000 | -18,421,000 | -251,683,000 | 71,894,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| net income per common share — basic and diluted | -330 | 695,000 | 695,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 19,300,000 | 15,701,000 | 15,372,000 | 8,278,000 | 6,427,000 | 5,270,000 | 4,753,000 | 156,682,000 | 4,635,000 | 137,436,000 | 117,344,000 | 8,758,000 | 104,491,000 | 8,196,500 | ||||||||||||||||||||||||||||||||||||||||||
| net income per common shares — basic and diluted | -400 | -320 | -270 | -250 | -220 | -220 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders per common shares – basic and diluted | -350 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding – basic and diluted | 125,178,517,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research revenue | 293,000 | 475,000 | 58,312,000 | 39,000 | 57,493,000 | 52,016,000 | 8,108,000 | 37,794,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| total revenue | 293,000 | 475,000 | 122,694,000 | 39,000 | 121,875,000 | 111,238,000 | 11,428,000 | 92,036,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| change in fair value of warrant liability | 2,461,000 | 517,000 | 1,291,000 | 4,118,000 | -3,218,000 | -113,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| collaboration and milestone revenue | 64,382,000 | 64,382,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| impairment of leasehold improvements | 1,030,000 | 1,030,000 | 1,030,000 | 1,030,000 | 257,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| in-process research and development | 418,000 | 418,000 | 418,000 | 418,000 | -210,604,000 | -210,604,000 | -176,661,000 | -176,661,000 | -141,859,000 | -141,859,000 | 104,500 | -113,061,000 | -113,061,000 | |||||||||||||||||||||||||||||||||||||||||||
| other (expense)/ income | 243,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before tax benefit | -63,379,250 | -253,517,000 | 89,546,000 | 89,546,000 | 62,931,000 | 62,931,000 | 48,374,000 | 48,374,000 | -28,439,000 | 32,786,000 | 32,786,000 | |||||||||||||||||||||||||||||||||||||||||||||
| deemed dividend | -19,424,000 | -4,856,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock accretion | -802,000 | -200,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders per common shares — basic and diluted | -290 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| collaboration revenue | 59,222,000 | 3,320,000 | 54,242,000 | 31,108,000 | 31,108,000 | 17,476,000 | 17,476,000 | 6,954,000 | 6,954,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| benefit from income taxes | 5,463,000 | 458,500 | 1,834,000 | 81,108,000 | 81,108,000 | 21,357,000 | 21,357,000 | 8,751,000 | 8,751,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| (benefit from)/benefit from income taxes | -918,000 | -918,000 | -454,000 | -454,000 | -454,000 | -454,000 | -454,000 | -454,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders per common share – basic and diluted |
We provide you with 20 years income statements for Amicus Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Amicus Therapeutics stock. Explore the full financial landscape of Amicus Therapeutics stock with our expertly curated income statements.
The information provided in this report about Amicus Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.